<p>Marex Group plc 在第二季度購買了 Sana Biotechnology, Inc.（NASDAQ:SANA - 免費報告）的新股份，根據其最近向 SEC 提交的 13F 文件。這家機構投資者購買了 3,817,780 股該公司的股票，價值約為 10,423,000 美元。Marex Group plc 在最近一個季度末持有 Sana Biotechnology 約 1.61% 的股份。</p>
<ul>
<li>可能還有時間投資這三隻熱門生物科技股</li>
</ul>
<p>其他一些對沖基金也買賣了該公司的股票。Corient Private Wealth LLC 在第二季度將其在 Sana Biotechnology 的持股增加了 264.7%。Corient Private Wealth LLC 現在擁有 1,136,000 股該公司的股票，價值 3,101,000 美元，此前在此期間又購買了 824,505 股。Captrust Financial Advisors 在第二季度將其在 Sana Biotechnology 的持股增加了 43.8%。Captrust Financial Advisors 現在擁有 15,793 股該公司的股票，價值 43,000 美元，此前在上個季度又購買了 4,807 股。BNP Paribas Financial Markets 在第二季度將其在 Sana Biotechnology 的股份增加了 46.9%。BNP Paribas Financial Markets 現在擁有 15,444 股該公司的股票，價值 42,000 美元，此前在此期間又購買了 4,931 股。Brevan Howard Capital Management LP 在第二季度將其在 Sana Biotechnology 的持股增加了 85.3%。Brevan Howard Capital Management LP 現在擁有 260,723 股該公司的股票，價值 712,000 美元，此前在上個季度又購買了 120,016 股。最後，Adage Capital Partners GP L.L.C. 在第二季度以約 1,916,000 美元的價格購買了 Sana Biotechnology 的新股份。目前，88.23% 的股票由對沖基金和其他機構投資者持有。</p>
<p>獲取 <strong>Sana Biotechnology</strong> 的提醒：</p>
<h2>Sana Biotechnology 價格表現</h2>
<p>SANA 股票在週五開盤價為 5.14 美元。該公司的 50 日簡單移動平均線為 4.50 美元，200 日簡單移動平均線為 3.76 美元。該股票的市值為 13.7 億美元，市盈率為 -5.30，貝塔係數為 1.95。Sana Biotechnology, Inc. 的一年低點為 1.26 美元，一年高點為 7.30 美元。</p>
<p>Sana Biotechnology（NASDAQ:SANA - 獲取免費報告）最近一次發佈季度財報是在 11 月 6 日，報告每股收益（EPS）為 -0.15 美元，超出分析師一致預期的 -0.18 美元，超出幅度為 0.03 美元。研究分析師平均預計 Sana Biotechnology, Inc. 在當前財年將發佈 -1.16 的每股收益。</p>
<h2>華爾街分析師觀點</h2>
<p>幾位股票研究分析師最近對該公司發表了看法。Weiss Ratings 在 12 月 8 日的研究報告中重申了對 Sana Biotechnology 股票的 &#34;賣出（d-）&#34; 評級。Citizens Jmp 在 10 月 30 日的研究報告中將 Sana Biotechnology 股票的目標價從 5.00 美元上調至 8.00 美元，並給予該公司 &#34;市場表現優於大盤&#34; 的評級。Wall Street Zen 在 11 月 22 日的研究報告中將 Sana Biotechnology 股票的評級從 &#34;持有&#34; 下調至 &#34;賣出&#34;。Wedbush 在 11 月 7 日的報告中將 Sana Biotechnology 股票的目標價從 5.00 美元上調至 6.00 美元，並給予該公司 &#34;表現優於大盤&#34; 的評級。最後，HC Wainwright 在 11 月 7 日的報告中將 Sana Biotechnology 股票的目標價從 11.00 美元下調至 9.00 美元，並對該股票給予 &#34;買入&#34; 評級。八位分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 &#34;適度買入&#34;，平均目標價為 8.33 美元。</p>
<p><strong>查看我們關於 Sana Biotechnology 的最新研究報告</strong></p>
<h2>Sana Biotechnology 公司簡介</h2>
<p>（免費報告）</p>
<p>Sana Biotechnology, Inc. 是一家生物科技公司，專注於利用工程細胞作為藥物。它開發了用於各種治療領域的體外和體內細胞工程平台，以滿足未滿足的治療需求，包括腫瘤學、糖尿病、中樞神經系統疾病、B 細胞介導的自身免疫等。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，而不是 Sana Biotechnology</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
<li>我在哪裏可以找到 52 周高點和低點？</li>
<li>為什麼亞馬遜可能在幾周內成為 300 美元的股票</li>
<li>資產配置：成功投資組合的關鍵。你在關注自己的投資組合嗎？</li>
<li>Adobe 在財報後獲得提振：長期前景看好</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Sana Biotechnology 嗎？</h2>
<p>在你考慮投資 Sana Biotechnology 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Sana Biotechnology 並不在名單上。</p>
<p>雖然 Sana Biotechnology 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

SANA

<p>Marex Group plc 在第二季度購買了價值 1042 萬美元的 Sana Biotechnology, Inc.的新股份，收購了 3,817,780 股。這項投資代表了對 Sana Biotechnology 約 1.61% 的持股比例。其他對沖基金也增加了在該公司的持倉。Sana Biotechnology 的股票在週五以 5.14 美元開盤，市值為 13.7 億美元。分析師對該股票的評級不一，平均評級為 “適度買入”，平均目標價為 8.33 美元</p>

<p>Marex Group plc purchased a new stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 3,817,780 shares of the company's stock, valued at approximately $10,423,000. Marex Group plc owned approximately 1.61% of Sana Biotechnology at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Marex Group plc 在第二季度購買了 Sana Biotechnology, Inc.（NASDAQ:SANA - 免費報告）的新股份，根據其最近向 SEC 提交的 13F 文件。這家機構投資者購買了 3,817,780 股該公司的股票，價值約為 10,423,000 美元。Marex Group plc 在最近一個季度末持有 Sana Biotechnology 約 1.61% 的股份。</p>
</div><ul>
<li>There May Still Be Time to Get in on These 3 Trending Biotechs</li>
</ul>
<div class="lb-trans"><ul>
<li>可能還有時間投資這三隻熱門生物科技股</li>
</ul>
</div><p>A number of other hedge funds have also bought and sold shares of the business. Corient Private Wealth LLC raised its holdings in Sana Biotechnology by 264.7% during the 2nd quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company's stock valued at $3,101,000 after acquiring an additional 824,505 shares during the period. Captrust Financial Advisors grew its position in shares of Sana Biotechnology by 43.8% in the second quarter. Captrust Financial Advisors now owns 15,793 shares of the company's stock valued at $43,000 after purchasing an additional 4,807 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Sana Biotechnology by 46.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company's stock valued at $42,000 after purchasing an additional 4,931 shares during the period. Brevan Howard Capital Management LP lifted its holdings in Sana Biotechnology by 85.3% during the 2nd quarter. Brevan Howard Capital Management LP now owns 260,723 shares of the company's stock worth $712,000 after purchasing an additional 120,016 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new position in Sana Biotechnology in the 2nd quarter worth about $1,916,000. 88.23% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些對沖基金也買賣了該公司的股票。Corient Private Wealth LLC 在第二季度將其在 Sana Biotechnology 的持股增加了 264.7%。Corient Private Wealth LLC 現在擁有 1,136,000 股該公司的股票，價值 3,101,000 美元，此前在此期間又購買了 824,505 股。Captrust Financial Advisors 在第二季度將其在 Sana Biotechnology 的持股增加了 43.8%。Captrust Financial Advisors 現在擁有 15,793 股該公司的股票，價值 43,000 美元，此前在上個季度又購買了 4,807 股。BNP Paribas Financial Markets 在第二季度將其在 Sana Biotechnology 的股份增加了 46.9%。BNP Paribas Financial Markets 現在擁有 15,444 股該公司的股票，價值 42,000 美元，此前在此期間又購買了 4,931 股。Brevan Howard Capital Management LP 在第二季度將其在 Sana Biotechnology 的持股增加了 85.3%。Brevan Howard Capital Management LP 現在擁有 260,723 股該公司的股票，價值 712,000 美元，此前在上個季度又購買了 120,016 股。最後，Adage Capital Partners GP L.L.C. 在第二季度以約 1,916,000 美元的價格購買了 Sana Biotechnology 的新股份。目前，88.23% 的股票由對沖基金和其他機構投資者持有。</p>
</div><p>Get <strong>Sana Biotechnology</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Sana Biotechnology</strong> 的提醒：</p>
</div><h2>Sana Biotechnology Price Performance</h2>
<div class="lb-trans"><h2>Sana Biotechnology 價格表現</h2>
</div><p>SANA stock opened at $5.14 on Friday. The firm has a 50 day simple moving average of $4.50 and a two-hundred day simple moving average of $3.76. The stock has a market cap of $1.37 billion, a PE ratio of -5.30 and a beta of 1.95. Sana Biotechnology, Inc. has a one year low of $1.26 and a one year high of $7.30.</p>
<div class="lb-trans"><p>SANA 股票在週五開盤價為 5.14 美元。該公司的 50 日簡單移動平均線為 4.50 美元，200 日簡單移動平均線為 3.76 美元。該股票的市值為 13.7 億美元，市盈率為 -5.30，貝塔係數為 1.95。Sana Biotechnology, Inc. 的一年低點為 1.26 美元，一年高點為 7.30 美元。</p>
</div><p>Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.03. On average, research analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Sana Biotechnology（NASDAQ:SANA - 獲取免費報告）最近一次發佈季度財報是在 11 月 6 日，報告每股收益（EPS）為 -0.15 美元，超出分析師一致預期的 -0.18 美元，超出幅度為 0.03 美元。研究分析師平均預計 Sana Biotechnology, Inc. 在當前財年將發佈 -1.16 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Sana Biotechnology in a research report on Monday, December 8th. Citizens Jmp boosted their price objective on shares of Sana Biotechnology from $5.00 to $8.00 and gave the company a &#34;market outperform&#34; rating in a research note on Thursday, October 30th. Wall Street Zen cut shares of Sana Biotechnology from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 22nd. Wedbush raised their price target on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an &#34;outperform&#34; rating in a report on Friday, November 7th. Finally, HC Wainwright decreased their price target on shares of Sana Biotechnology from $11.00 to $9.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, November 7th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and an average price target of $8.33.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對該公司發表了看法。Weiss Ratings 在 12 月 8 日的研究報告中重申了對 Sana Biotechnology 股票的 &#34;賣出（d-）&#34; 評級。Citizens Jmp 在 10 月 30 日的研究報告中將 Sana Biotechnology 股票的目標價從 5.00 美元上調至 8.00 美元，並給予該公司 &#34;市場表現優於大盤&#34; 的評級。Wall Street Zen 在 11 月 22 日的研究報告中將 Sana Biotechnology 股票的評級從 &#34;持有&#34; 下調至 &#34;賣出&#34;。Wedbush 在 11 月 7 日的報告中將 Sana Biotechnology 股票的目標價從 5.00 美元上調至 6.00 美元，並給予該公司 &#34;表現優於大盤&#34; 的評級。最後，HC Wainwright 在 11 月 7 日的報告中將 Sana Biotechnology 股票的目標價從 11.00 美元下調至 9.00 美元，並對該股票給予 &#34;買入&#34; 評級。八位分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 &#34;適度買入&#34;，平均目標價為 8.33 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Sana Biotechnology</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Sana Biotechnology 的最新研究報告</strong></p>
</div><h2>Sana Biotechnology Profile</h2>
<div class="lb-trans"><h2>Sana Biotechnology 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.</p>
<div class="lb-trans"><p>Sana Biotechnology, Inc. 是一家生物科技公司，專注於利用工程細胞作為藥物。它開發了用於各種治療領域的體外和體內細胞工程平台，以滿足未滿足的治療需求，包括腫瘤學、糖尿病、中樞神經系統疾病、B 細胞介導的自身免疫等。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Sana Biotechnology</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
<li>Where Do I Find 52-Week Highs and Lows?</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，而不是 Sana Biotechnology</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
<li>我在哪裏可以找到 52 周高點和低點？</li>
<li>為什麼亞馬遜可能在幾周內成為 300 美元的股票</li>
<li>資產配置：成功投資組合的關鍵。你在關注自己的投資組合嗎？</li>
<li>Adobe 在財報後獲得提振：長期前景看好</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SANA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sana Biotechnology Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Sana Biotechnology 嗎？</h2>
</div><p>Before you consider Sana Biotechnology, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Sana Biotechnology 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Sana Biotechnology 並不在名單上。</p>
</div><p>While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Sana Biotechnology 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Marex Group plc 在 Sana Biotechnology, Inc. $SANA 中建立了價值 1042 萬美元的頭寸